



Grant Thornton

An instinct for growth™

Glenmark Pharmaceuticals SA La Chaux-de-Fonds

Financial Statements
for the Year ended March 31, 2018
and Report of the Statutory Auditor





Grant Thornton

An instinct for growth™

Grant Thornton AG
20 Rte de Pré-Bois
P.O. Box 1892
CH-1215 Genf
T +41 22 799 47 99
F +41 22 799 47 90
www.grantthornton.ch

Report of the Statutory Auditor

To the General Meeting of the Shareholders of
Glenmark Pharmaceuticals SA, La Chaux-de-Fonds

Report of the Statutory Auditor on the Financial Statements

As statutory auditor, we have audited the accompanying financial statements of Glenmark Pharmaceuticals SA, which comprise the balance sheet, income statement, and notes for the year ended March 31, 2018.

Board of Directors' Responsibility

The Board of Directors is responsible for the preparation of the financial statements in accordance with the requirements of Swiss law and the Company's articles of incorporation. This responsibility includes designing, implementing and maintaining an internal control system relevant to the preparation of financial statements that are free from material misstatement, whether due to fraud or error. The Board of Directors is further responsible for selecting and applying appropriate accounting policies and making accounting estimates that are reasonable in the circumstances.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Swiss law and Swiss Auditing Standards. Those standards require that we plan and perform the audit to obtain reasonable assurance whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers the internal control system relevant to the entity's preparation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control system. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of accounting estimates made, as well as evaluating the overall presentation of the financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements for the year ended March 31, 2018 comply with Swiss law and the Company's articles of incorporation.

Other Matter

The financial statements of Glenmark Pharmaceuticals SA for the year ended March 31, 2017, were audited by another auditor who expressed an unmodified opinion on those statements on May 8, 2017.



Grant Thornton

An instinct for growth™

Report on Other Legal Requirements

We confirm that we meet the legal requirements on licensing according to the Auditor Oversight Act (AOA) and independence (article 728 CO) and that there are no circumstances incompatible with our independence.

In accordance with article 728a paragraph 1 item 3 CO and Swiss Auditing Standard 890, we confirm that an internal control system exists, which has been designed for the preparation of financial statements according to the instructions of the Board of Directors.

We draw attention to the fact that the Company's liabilities exceed its assets on the basis of book values. As the parent company has subordinated claims of totalling CHF 202'063'793 to the claims of all other creditors, the Board of Directors has not notified the court, as permitted under article 725 para. 2 of the Swiss Code of Obligations.

We recommend that the financial statements submitted to you be approved.

Geneva, May 29, 2018

Grant Thornton AG

Erich Bucher
Audit Expert
Auditor in charge

Moritz Herbst

Enclosures:

- Financial statements (balance sheet, income statement, and notes)



Glenmark Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland

Balance sheet as at

31.03.2018

31.03.2017

Assets

(in Swiss francs)

Current assets

Cash and cash equivalents

1'720'272

1'599'073

Accounts receivables from group companies

4'825'148

4'910'819

Other current receivables

507'397

535'167

Inventories

456'270

383'609

Accrued income and prepaid expenses

90'929

-

Total current assets

7'600'016

7'428'668

Non-current assets

Financial assets

243'037

240'714

Investments

1

1

Property, plant and equipment

4'221'834

3'078'074

Intangible assets

165'992'906

155'744'727

Total non-current assets

170'457'778

159'063'515

Total assets

178'057'794

166'492'183



Glenmark Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland

Balance sheet as at	31.03.2018	31.03.2017
Liabilities		
	<i>(in Swiss francs)</i>	
<u>Short-term liabilities</u>		
Accounts payable	59'931'664	51'500'995
<i>due to third parties</i>	8'514'816	4'844'085
<i>due to group companies</i>	50'147'558	36'050'352
<i>due to shareholders</i>	1'269'290	10'606'557
Short-term interest-bearing liabilities	151'265	187'148
<i>due to third parties</i>	151'265	187'148
Other short-term liabilities	321'856	208'218
Short-term provisions and accrued expenses	1'624'300	1'705'900
Total short-term liabilities	62'029'085	53'602'262
<u>Long-term liabilities</u>		
Long-term interest-bearing liabilities	80'585'559	70'114'918
<i>due to third parties</i>	285'705	436'675
<i>due to shareholders</i>	80'299'854	69'678'244
Other long-term liabilities	202'063'793	190'349'649
<i>Subordinated loan from shareholder</i>	202'063'793	190'349'649
Total long-term liabilities	282'649'352	260'464'567
<u>Shareholders' equity</u>		
Share capital	50'000'000	50'000'000
Legal capital reserves	1'500'000	1'500'000
<i>Other capital reserves</i>	1'500'000	1'500'000
Accumulated deficit for the year	(218'120'643)	(199'074'646)
<i>Accumulated losses brought forward</i>	(199'074'646)	(120'423'300)
<i>Loss for the year</i>	(19'045'997)	(78'651'346)
Total shareholders' equity	(166'620'643)	(147'574'646)
Total liabilities and shareholders' equity	178'057'794	166'492'183



Glenmark Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland

Profit and loss statement for the financial year ended

31.03.2018

31.03.2017

(in Swiss francs)

Revenue from sales of goods and services	46'890'507	44'371'301
Costs of goods	(9'607'208)	(23'655'062)
Gross profit	37'283'299	20'716'239
Staff expenses	(15'853'967)	(13'559'926)
Administrative expenses	(312'070)	(213'173)
Depreciation and valuation adjustments	(10'368'552)	(41'266'243)
Research and Development expenses	(37'690'683)	(29'057'171)
<u>Other operating expenses</u>	<u>(3'154'993)</u>	<u>(3'058'767)</u>
Operating expenses	(67'380'265)	(87'155'280)
Loss for the year before interest and taxes	(30'096'965)	(66'439'041)
Financial income	16'367'341	955'770
Financial expenses	(5'698'114)	(13'536'984)
Non-operating income	383'024	368'628
Non-operating expenses	(1'283)	(0)
Loss for the year before taxes	(19'045'997)	(78'651'627)
Direct taxes	-	281
Loss for the year	(19'045'997)	(78'651'346)



Notes to the financial statements

GLENMARK SIGNIFICANT ACCOUNTING POLICIES

- **Basis of preparation**

These financial statements have been prepared in accordance with the provisions of commercial accounting as set out in the Swiss Code of Obligations (Art. 957 to 963b CO, effective since 1 January 2013).

- **Foreign currency transactions**

Transactions in foreign currencies are converted into CHF at the prevailing exchange rate on the transaction date. Balance sheet items in foreign currency are converted using the year-end exchange rate. Exchange differences, except for unrealized gains which are deferred, are included in the determination of net income

- **Fixed assets (Property, plant and equipment)**

Fixed assets are stated at cost less accumulated depreciation and amortization.

The estimated useful lives are as follows:

- Factory and administrative buildings (leased)	5 years
- Plant and equipment	2.5 years
- Furniture, fixtures and office equipment	2.5 years
- Vehicles	2.5 years
- Computer equipment	2.5 years

Depreciation methods, useful lives and residual values are reviewed at each reporting date.

- **Intangible assets**

Research and development

Expenditures on research activities undertaken with the prospect of gaining new scientific or technical knowledge and understanding are recognized in profit or loss when incurred.

Development activities involve a plan or design for the production of new or substantially improved products and processes. Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditures are capitalized only if development costs can be measured reliably by project, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient technical financial and other resources to complete the development and to use or sell the asset.

The expenditures capitalized include the cost of materials and other costs directly attributable to preparing the asset for its intended use. Other development expenditures are recognized in profit or loss as incurred.



Notes to the financial statements

The Company's internal drug development expenditures are capitalized only if they meet the recognition criteria as mentioned above. Where regulatory and other uncertainties are such that the criteria are not met, the expenditures are recognized in profit or loss as incurred. This is almost invariably the case prior to approval of the drug by the relevant regulatory authority. Where, however, the recognition criteria are met, intangible assets are capitalized and amortized on a straight-line basis over their useful economic lives from product launch.

Intangible assets relating to products in development, other intangible assets not available for use and intangible assets having indefinite useful life are subject to impairment testing at each balance sheet date. All other intangible assets are tested for impairment when there are indications that the carrying value may not be recoverable. Any impairment losses are recognized immediately in the income statement.

Other intangible assets

Other intangible assets such as Brands that are acquired by the Company, which have finite useful lives, are measured at cost less accumulated amortization and accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate.

Amortization

Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of intangible assets, other than for goodwill, intangible assets not available for use and intangible assets having indefinite life, from the date that they are available for use.

The estimated useful lives are as follows:

- IP on Brands 5 years from acquisition
- Molecules 10 years from the date of the launch on the market

- **Impairment of assets**

The Company assesses at each Balance Sheet date whether there is any indication that assets may be impaired. If any such indication exists, the Company estimates the recoverable amount of the cash generating unit to which the assets belong. If the recoverable amount of the cash generating unit to which the assets belong is less than its carrying amount, the carrying amount is reduced to its recoverable amount. The recoverable amount is higher of the value in use and realizable value.

The reduction is treated as an impairment loss and is recognized in the Statement of Profit and Loss.

If, at the Balance Sheet date, there is an indication that a previously assessed impairment loss no longer exists, the recoverable amount is reassessed and the asset is reflected at the recoverable amount.

- **Revenue recognition**

All income whether for goods or services, operating or non-operating needs to be accounted for on accrual basis except for molecule sales which will be accounted on cash basis.



Glenmark Pharmaceuticals SA

La Chaux-de-Fonds, Switzerland

Notes to the financial statements

(in Swiss francs)

Details, analyses and explanations to the financial statements

The number of full-time equivalents did not exceed 250 on an annual average basis.

Inventories

CHF	31.03.2018	31.03.2017
Raw materials, consumables and supplies	456'270	383'609
Total	456'270	383'609

Property, Plant, and Equipment

The Property, Plant and Equipment net position in the balance sheet includes a Gross value of KCHF 24'572 and an Accumulated depreciation of KCHF 20'350.

Intangible assets

The intangible asset position in the balance sheet consists of Intellectual property rights in products for kCHF 36'870 and molecules under developmeents for kCHF 129'122.

Other operating expenses

CHF	31.03.2018	31.03.2017
Premises Rent, Maintenance & Energy	2'047'459	1'871'330
Travel expenses	609'698	416'200
Professional services	497'836	771'237
Total	3'154'993	3'058'767

Collateral for third-party liabilities

CHF	31.03.2018	31.03.2017
Deposit	243'037	240'714
Total	243'037	240'714

Pension liabilities

On 31st March 2018, there is no liability towards the pension fund scheme.

Lease liabilities (not terminable or expiring within 12 months of balance sheet date)

	Residual term (yrs)	31.03.2018	31.03.2017
AMAG Leasing		0	5'819

Group VAT

Glenmark Pharmaceuticals SA, Glenmark Holding SA and Glenmark Specialty SA are in the same VAT group and jointly responsible.

Loan subordination

Glenmark Holding SA has entered into a specific agreement with Glenmark Pharmaceuticals SA as to subordinate part of their claims to the extent of the capital deficit, according to Art. 725 Code of Obligations.

Significant events occurring after the balance sheet date

none